Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 7,718 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 2 Clear all
Completed Not applicable Interventional Results available

Selecting Effective Combinations of Treatment for Low Back Pain

NCT03520387
View directory record Official record
Conditions
Low Back Pain
Interventions
Lumbar medial branch nerve radiofrequency ablation (LRFA), Simulated LRFA with targeted steroid injections, AcTIVE-CBT, TBSCE
Procedure · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

NCT01244763
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
35
States / cities
Mobile, Alabama • Pine Bluff, Arkansas • Azusa, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 1 Interventional

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

NCT02983006
View directory record Official record
Conditions
Melanoma
Interventions
DS-8273a, Nivolumab
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care

NCT02933567
View directory record Official record
Conditions
Psychosis
Interventions
CSC OnDemand
Other
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 20, 2026, 5:53 AM EDT
Recruiting Phase 2 Interventional

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Momelotinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Goodyear, Arizona • Duarte, California • Irvine, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain GABA Levels and Treatment Response in Major Depressive Disorder

NCT00464711
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 1 Interventional

Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma

NCT04716699
View directory record Official record
Conditions
Glioblastoma
Interventions
Biospecimen Collection, Lidocaine, Resection
Procedure · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02227199
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Carboplatin, Etoposide, Ifosfamide, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 20, 2026, 5:53 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

NCT07109414
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
NP-G2-044, PLD
Drug
Lead sponsor
Novita Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Phoenix, Arizona • Shreveport, Louisiana • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of Male Hormones on Regional Fat Metabolism

NCT01160328
View directory record Official record
Conditions
Obesity
Interventions
Leuprolide, Testosterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 20, 2026, 5:53 AM EDT
Not listed Not applicable Interventional

Priming With tDCS: Expanding the Window of Recovery in Chronic Stroke

NCT03964467
View directory record Official record
Conditions
Upper Extremity Paresis
Interventions
transcranial direct current stimulation
Device
Lead sponsor
University of the Sciences in Philadelphia
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 20, 2026, 5:53 AM EDT
Not listed Not applicable Interventional

Study of Nucel for One and Two Level Lumbar Interbody Fusion

NCT02808234
View directory record Official record
Conditions
Degenerative Disc Disease, Spondylolisthesis, Spondylosis
Interventions
One or two level lumbar interbody fusion surgery, Nucel
Procedure · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Tampa, Florida • Shreveport, Louisiana • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

NCT02494921
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel-PNP, Ribociclib, Prednisone, Filgrastim
Drug
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

NCT02516332
View directory record Official record
Conditions
Anxiety, Cardiovascular Disease
Interventions
Lexapro, Placebo, Supervised Aerobic Exercise
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 20, 2026, 5:53 AM EDT
Recruiting Phase 1 Interventional

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

NCT05768932
View directory record Official record
Conditions
Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
Interventions
BAL0891, Tislelizumab, Paclitaxel
Drug · Combination Product
Lead sponsor
SillaJen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 20, 2026, 5:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

NCT02743611
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
Interventions
BPX-701, Rimiducid
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Denver, Colorado • Portland, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Not applicable Interventional

Prevention Program to Reduce Injury Disparities Among Latino Day Laborers

NCT04378348
View directory record Official record
Conditions
Work-related Injury
Interventions
Motivational Interview (MI), Participatory Group Activity, Control Condition
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 20, 2026, 5:53 AM EDT
Active, not recruiting Phase 1 Interventional

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

NCT05015426
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gamma Delta T-Cell Infusion
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Foundations for Health

NCT01304615
View directory record Official record
Conditions
Overweight, Obese
Interventions
Decrease Energy Density of the Diet, Increase Steps per Day, Consumption of Self-made Meals
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 20, 2026, 5:53 AM EDT
Recruiting Phase 2 Interventional

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

NCT06698250
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Zanzalintinib, Durvalumab, Tremelimumab
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ultrasound Guided Local Anesthetic Block: Thoracolumbar Interfascial Plane

NCT02297191
View directory record Official record
Conditions
Healthy
Interventions
Thoracolumbar Interfascial Plane Block, Ropivicaine
Procedure · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)

NCT02806947
View directory record Official record
Conditions
Acute GVHD
Interventions
Sirolimus, Prednisone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
21
States / cities
Duarte, California • Los Angeles, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

NCT00432185
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Mesa, Arizona • Oceanside, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 20, 2026, 5:53 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

NCT02243189
View directory record Official record
Conditions
Healthy, Asthma
Interventions
JNJ-43260295, Placebo, Nasal Allergen Challenge
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 20, 2026, 5:53 AM EDT